JP2023538590A5 - - Google Patents

Info

Publication number
JP2023538590A5
JP2023538590A5 JP2023512048A JP2023512048A JP2023538590A5 JP 2023538590 A5 JP2023538590 A5 JP 2023538590A5 JP 2023512048 A JP2023512048 A JP 2023512048A JP 2023512048 A JP2023512048 A JP 2023512048A JP 2023538590 A5 JP2023538590 A5 JP 2023538590A5
Authority
JP
Japan
Application number
JP2023512048A
Other languages
Japanese (ja)
Other versions
JP2023538590A (ja
JPWO2022040246A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046392 external-priority patent/WO2022040246A1/en
Publication of JP2023538590A publication Critical patent/JP2023538590A/ja
Publication of JP2023538590A5 publication Critical patent/JP2023538590A5/ja
Publication of JPWO2022040246A5 publication Critical patent/JPWO2022040246A5/ja
Pending legal-status Critical Current

Links

JP2023512048A 2020-08-17 2021-08-17 がんの処置のための骨髄由来抑制細胞機能の免疫調節 Pending JP2023538590A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063066806P 2020-08-17 2020-08-17
US202063066807P 2020-08-17 2020-08-17
US63/066,806 2020-08-17
US63/066,807 2020-08-17
PCT/US2021/046392 WO2022040246A1 (en) 2020-08-17 2021-08-17 Immune modulation of myeloid derived suppressive cell function for cancer treatment

Publications (3)

Publication Number Publication Date
JP2023538590A JP2023538590A (ja) 2023-09-08
JP2023538590A5 true JP2023538590A5 (https=) 2024-08-23
JPWO2022040246A5 JPWO2022040246A5 (https=) 2024-08-23

Family

ID=80323241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512048A Pending JP2023538590A (ja) 2020-08-17 2021-08-17 がんの処置のための骨髄由来抑制細胞機能の免疫調節

Country Status (9)

Country Link
US (1) US20230398146A1 (https=)
EP (1) EP4196122A4 (https=)
JP (1) JP2023538590A (https=)
KR (1) KR20230079036A (https=)
CN (1) CN116322702A (https=)
AU (1) AU2021329884A1 (https=)
CA (1) CA3189611A1 (https=)
IL (1) IL300479A (https=)
WO (1) WO2022040246A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115054579B (zh) * 2022-05-30 2023-06-30 浙江大学 一种活性氧响应性梯度递药的纳米粒子关节炎药物及其制备方法
EP4648778A1 (en) * 2023-01-09 2025-11-19 National Health Research Institutes Method for treating netosis-mediated diseases
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025259942A1 (en) * 2024-06-13 2025-12-18 Roswell Park Cancer Institute Corporation Targeting immunosuppressive tumor microenvironment by blocking nicotinamide phosphoribosyltransferase (nampt) in myeloid cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20110305765A1 (en) * 2008-11-21 2011-12-15 Board Of Regents, The University Of Texas System Preparation and methodology of silk fibroin nanoparticles
CN101612400A (zh) * 2009-07-22 2009-12-30 陈志龙 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用
EP2905029B1 (en) * 2012-10-04 2018-11-21 Shionogi&Co., Ltd. Drug for inhibiting malignant tumor metastasis
US9463198B2 (en) * 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20170360912A1 (en) * 2014-12-17 2017-12-21 Socovar, L.P. Chitosan-based hydrogel and applications thereof.
WO2016141151A1 (en) * 2015-03-03 2016-09-09 University Of Miami Nanoparticle conjugates and uses thereof
CA2990852A1 (en) * 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
FI3922279T3 (fi) * 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
JP7404230B2 (ja) * 2017-09-18 2023-12-25 トラスティーズ オブ ボストン ユニバーシティ ネトーシスおよび好中球活性化を処置するための方法
IL305483A (en) * 2018-03-20 2023-10-01 Dana Farber Cancer Inst Inc Preparations and methods for the treatment of cancer
CN113766929A (zh) * 2019-05-02 2021-12-07 斯蒂米特公司 癌症治疗
CN114401991A (zh) * 2019-06-04 2022-04-26 维西欧制药公司 用于调节髓系细胞炎性表型的抗siglec-9组合物和方法及其用途
KR20230041032A (ko) * 2020-07-17 2023-03-23 서지 테라퓨틱스, 인크. 중합체 복합 제제를 포함하는 제제 및 조성물

Similar Documents

Publication Publication Date Title
JP2023538590A5 (https=)
JP2022531184A5 (https=)
CN305964458S (https=)
CN305961677S (https=)
CN305537016S (https=)
CN305535759S (https=)
CN305535683S (https=)
CN305535104S (https=)
CN305533783S (https=)
CN305533329S (https=)
CN305531768S (https=)
CN305530250S (https=)
CN305530247S (https=)
CN305529367S (https=)
CN305528350S (https=)
CN306774895S (https=)
CN305965836S (https=)
CN305965231S (https=)
CN305962747S (https=)
CN305960579S (https=)
CN305959121S (https=)
CN305957247S (https=)
CN305956424S (https=)
CN305955671S (https=)
CN305952761S (https=)